Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.641 USD | -0.25% | -0.71% | -14.03% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Financials (USD)
Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 13.52M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 64.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 45.1 x |
P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.77
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Traws Pharma, Inc.
1 day | -0.25% | ||
1 week | -0.71% | ||
Current month | -2.88% | ||
1 month | -7.86% | ||
3 months | -4.33% | ||
6 months | -1.99% | ||
Current year | -14.03% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 0.641 | -0.25% | 55,246 |
24-05-16 | 0.6426 | -2.25% | 51,288 |
24-05-15 | 0.6574 | +1.12% | 28,934 |
24-05-14 | 0.6501 | +0.70% | 53,056 |
24-05-13 | 0.6456 | 0.00% | 31,930 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.03% | 13.52M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- TRAW Stock